Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is a promising investment option due to its unique business model and strategic partnerships with pharmaceutical companies. With a strong focus on sustainability and responsible business practices, the company has a diverse portfolio of assets and continues to make acquisitions to drive growth and profitability. Despite potential risks, Ligand's recent investments and raised stock price target indicate a positive outlook for the company's future performance.

Bears say

Ligand Pharmaceuticals is heavily reliant on royalty revenue, which poses a risk if sales of the company's partnered products slow down or decline. The company's business model is also heavily dependent on acquisitions and partnerships, which may not pan out as expected and could negatively impact the company's operations. Additionally, the company faces risks related to its drugs in development, such as clinical trial disappointments or failure to receive approvals. Despite its efforts towards sustainability and diversification, there is still a potential for setbacks and challenges in the company's operations.

Ligand Pharmaceuticals (LGND) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $326, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $326, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.